Natriuretic peptides as cardiac markers in clinical practice;Natriuretiske peptider som hjertemarkører i klinisk praksis

Ugeskrift for Laeger

Volumn 172, Issue 30, 2010, Pages

  Veien, Karsten Tange ^a   Hildebrandt, Per ^a   Gøetze, Jens Peter ^a   Nielsen, Olav Wendelboe ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; AGED; BLOOD; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; REFERENCE VALUE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77955302105     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
2. Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
3. Magga J, Vuolteenaho O, Tokola H et al. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med 1998;30 Suppl 1:39-45.
4. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;50:1503-10.
5. Liang F, O'Rear J, Schellenberger U et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
6. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
7. Daniels LB, Allison MA, Clopton P et al. Use of natriuretic peptides in pre-participation screening of college athletes. Int J Cardiol 2008;124:411-4.
8. Galasko GI, Lahiri A, Barnes SC et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76.
9. Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.
10. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
11. Nielsen LS, Svanegaard J, Klitgaard NA et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6:63-70.
12. Zaphiriou A, Robb S, Murray-Thomas T et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537-41.
13. Gustafsson F, Steensgaard-Hansen F, Badskjaer J et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 2005;11(5 Suppl):S15-20.
14. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101:9-15.
15. Atisha D, Bhalla MA, Morrison LK et al. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction. Am Heart J 2004;148:518-23.
16. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
17. Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004;110:1780-6.
18. Apple FS, Wu AH, Jaffe AS et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 2008;41:222-6.
19. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 2008;29:2388-442.
20. Nielsen OW, McDonagh TA, Robb SD et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20.
21. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53.
22. Raymond I, Groenning BA, Hildebrandt PR et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.
23. Hildebrandt P, Boesen M, Olsen M et al. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6:313-7.
24. Silvet H, Young-Xu Y, Walleigh D et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003;92:1124-7.
25. Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90.
26. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.
27. van Kraaij DJ, Jansen RW, Sweep FC et al. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail 2003;5:47-53.
28. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
29. Davis ME, Richards AM, Nicholls MG et al Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977-85.
30. Yoshizawa A, Yoshikawa T, Nakamura I et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J Card Fail 2004;10:310-5.
31. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
32. Januzzi JL, van Kimmenade R, Lainchbury J et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
33. Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.
34. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
35. Gaede P, Hildebrandt P, Hess G et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156-63.
36. Kragelund C, Gronning B, Kober L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
37. James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
38. Kruger S, Graf J, Merx MW et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004;147:60-5.
39. Jensen JK, Mickley H, Bak S et al. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis 2006;22:439-44.
40. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9.